MedTrace Logo

Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study

NCT00706134 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 756

Last updated 2011-06-28

Study results available
· View outcomes & findings →

Summary

This study will evaluate the efficacy and safety of aliskiren 75 mg, 150 mg, and 300 mg in elderly patients with essential hypertension when given with a light meal.

Conditions

Interventions

DRUG

Placebo

Placebo tablet taken once daily in the morning with a light meal.

DRUG

Aliskiren 75 mg

Aliskiren 75 mg tablet taken once daily in the morning with a light meal.

DRUG

Aliskiren 150 mg

Aliskiren 150 mg tablet taken once daily in the morning with a light meal.

DRUG

Aliskiren 300 mg

Aliskiren 300 mg tablet taken once daily in the morning with a light meal.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • Argentina
  • Czechia
  • Germany
  • Iceland
  • Italy
  • Netherlands
  • Poland
  • Slovakia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00706134 on ClinicalTrials.gov